Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

5.3K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.3K
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

7.6K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.6K
Persuasion Strategies01:52

Persuasion Strategies

43.0K
Researchers have tested many persuasion strategies, including the foot-in-the door and the door-in-the-face techniques, in a variety of contexts. Ultimately, the principles are effective in selling products and changing people’s attitude, ideas, and behaviors (Cialdini & Goldstein, 2004).
43.0K
Vaccinations01:51

Vaccinations

51.3K
Overview
51.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The atypical E3 ligase HOIL-1 safeguards the ribosome during cellular stress.

Nature cell biology·2026
Same author

Discovery of a Highly Potent and Selective Small-Molecule Inhibitor of <i>In Vivo</i> Anaerobic Choline Metabolism by Human Gut Bacteria.

Journal of medicinal chemistry·2026
Same author

Correction: Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation.

RSC chemical biology·2026
Same author

Chemoselective Synthesis of δ-Amino Alcohols from Chiral 1,4-Diols Catalyzed by an NHC-Ir(III) Complex.

Organic letters·2026
Same author

Quantitative Degradation Rate Assessment of bioPROTACs Based on Peptide Degrons, E3 Domains, Adapters and Conjugated Small Molecules.

ACS chemical biology·2026
Same author

Design and Application of Cereblon-Recruiting Prodegraders.

Journal of the American Chemical Society·2025

Related Experiment Video

Updated: Jan 23, 2026

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

4.5K

PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Mariell Pettersson1, Craig M Crews1

  • 1Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06511, USA.

Drug Discovery Today. Technologies
|June 16, 2019
PubMed
Summary

PROteolysis Targeting Chimeras (PROTACs) offer a novel event-driven approach to degrade target proteins, expanding therapeutic options beyond traditional small molecule inhibitors. This technology is crucial for addressing previously "undruggable" targets.

More Related Videos

Tissue Targeted Embryonic Chimeras: Zebrafish Gastrula Cell Transplantation
18:57

Tissue Targeted Embryonic Chimeras: Zebrafish Gastrula Cell Transplantation

Published on: September 11, 2009

19.8K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K

Related Experiment Videos

Last Updated: Jan 23, 2026

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

4.5K
Tissue Targeted Embryonic Chimeras: Zebrafish Gastrula Cell Transplantation
18:57

Tissue Targeted Embryonic Chimeras: Zebrafish Gastrula Cell Transplantation

Published on: September 11, 2009

19.8K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K

Area of Science:

  • Drug Discovery
  • Molecular Pharmacology
  • Biochemistry

Background:

  • Current therapeutics primarily use small molecules with occupancy-driven pharmacology, leading to temporary target inhibition.
  • A significant portion of the proteome remains
  • undruggable
  • with existing modalities.
  • Novel therapeutic approaches with alternative modes of action are needed.

Purpose of the Study:

  • To review the developmental milestones of PROteolysis Targeting Chimera (PROTAC) technology.
  • To highlight recent key findings and advancements in PROTAC research.
  • To outline future directions for PROTAC-based drug discovery.

Main Methods:

  • Review of scientific literature and recent publications on PROTAC technology.
  • Analysis of the mechanism of action for heterobifunctional PROTACs.
  • Discussion of the ubiquitin-proteasome system's role in PROTAC-mediated degradation.

Main Results:

  • PROTACs represent an attractive, event-driven alternative to occupancy-driven pharmacology.
  • Heterobifunctional PROTACs leverage the ubiquitin-proteasome system for targeted protein degradation.
  • Recent advancements have expanded the scope and efficacy of PROTAC technology.

Conclusions:

  • PROTAC technology is a promising modality for developing novel therapeutics.
  • This approach enables targeting of previously
  • undruggable
  • proteins.
  • Continued research into PROTACs holds significant potential for future drug discovery.